Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 2Phase 4 1Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 2Gastrointestinal 2Gynecologic 1

Conditions

Ovarian Neoplasms 225Uterine Cervical Neoplasms 181Fallopian Tube Neoplasms 93Carcinoma, Ovarian Epithelial 85Endometrial Neoplasms 74Neoplasms 37Uterine Cervical Dysplasia 35Papillomavirus Infections 35Breast Neoplasms 26Peritoneal Neoplasms 25Vulvar Neoplasms 23Condylomata Acuminata 22Vaginal Neoplasms 18Recurrence 16Testicular Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Burkitt Lymphoma 12Brenner Tumor 12Primary Myelofibrosis 11Multiple Myeloma 11Lymphoma, Non-Hodgkin 11Lymphoma, Mantle-Cell 11Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myeloid, Chronic-Phase 11Leukemia, Myeloid, Accelerated Phase 11Leukemia, Lymphocytic, Chronic, B-Cell 11Blast Crisis 11

Interventions

lanreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Intestinal Obstruction × Gynecologic × Clear all
NCT00216372 2020-11-05

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

Ipsen

Phase 3 Completed
80 enrolled
Gynecologic

Carcinoma, Intestinal Obstruction, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡